Anika Therapeutics | ANIK - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Abbott USD 3.27B 138M 2026-03
Agenus USD 10.56M 13.04M 2025-12
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 41.74M 4.28M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.26M 34.78M 2026-03
Integra LifeSciences USD 178.24M 21.79M 2026-03
Intrexon USD 10.31M 41K 2024-06
J&J USD 6.03B 719M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Ligand Pharmaceuticals USD 20.84M 4.19M 2026-03
MacroGenics USD 7.94M 1.96M 2025-12
Merit Medical Systems USD 110.47M 4.36M 2026-03
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.33B 419M 2026-03
Smith & Nephew USD 1.42B 65M 2025-12
Stryker USD 2.15B 17M 2026-03
Veracyte USD 50.84M 7.53M 2026-03
Xencor USD 82.12M 65.08M 2026-03
Zimmer Biomet Holdings USD 849.9M 5.8M 2026-03